Clinical validation Leverage ongoing and past clinical collaborations (University of Miami Health System) and in vitro/in vivo data on V.Dox technology to position Vomaris as a validated antimicrobial wound care and biofilm disruption solution for hospitals, clinics, and surgical centers pursuing innovative infection control.

Expansion opportunities capitalize on the recent expansion into PPE applications and the established wound care portfolio to cross-sell to providers seeking integrated antisepsis across devices, dressings, and personal protective equipment across inpatient and outpatient settings.

Small team advantage Target strategic partners and distribution channels that can scale with a small, nimble company; emphasize flexibility, rapid adoption, and co-development potential with large distributors that serve medical facilities and wound care pathways.

Funding readiness Position Vomaris as an innovative biotech with substantial venture funding history and a clear pipeline; engage potential investors and grant programs to accelerate clinical trials, manufacturing scale, and broader product rollout.

Competitive positioning Differentiate from conventional antimicrobial approaches by highlighting wireless microcurrent generation, reduced need for ionic silver or surfactants, and the ability to tackle multi-drug resistant organisms and biofilms to win contracts with hospitals, long-term care facilities, and wound care centers.